Research Article
Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands
Table 4
Results presenting outpatient chemotherapy visits and data relating to AEs and hospital visits relating to AEs.
| | Outpatient visits | Hospitalizations, outpatient visits, and number of total AEs | Clinical practice | Outpatient chemotherapy visits total | Hospitalizations due to short-term grade III/IVs AEs total | Outpatient visits due to short-term AE total | Number of AE total (short term and long term) |
| Oncotype DX test | 4,937 | 97 | 482 | 505 | No genomic test | 18,286 | 361 | 1,784 | 1,869 | MammaPrint | 9,875 | 195 | 964 | 1,009 | Difference between Oncotype DX test vs. no genomic test | -13,349 | -264 | -1,303 | -1,364 | Difference between Oncotype DX test vs. MammaPrint | -4,937 | -97 | -482 | -505 |
|
|
Abbreviation: AEs = adverse events.
|